Name	: Mr. SRINIVASAN R			
PID No.	: MED110975721	Register On : 2	3/02/2022 11:12 AM	m
SID No.	: 1802207928	Collection On : 2	23/02/2022 11:38 AM	
Age / Sex	: 32 Year(s) / Male	Report On :	23/02/2022 10:07 PM	MEDALL
Туре	: OP	Printed On : 2	24/02/2022 9:57 AM	
Ref. Dr	: MediWheel			
Investiga	ation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
TYPINC (EDTA Bl	GROUPING AND Rh G ood/Agglutination) RETATION: Reconfirm the Blood g	'B' 'Positive'	e blood transfusion	
	e Blood Count With - ESR			
Haemog (EDTA Bl	lobin ood/Spectrophotometry)	14.9	g/dL	13.5 - 18.0
	Cell Volume(PCV)/Haematocrit ood/Derived from Impedance)	43.5	%	42 - 52
RBC Co (EDTA Bl	unt ood/Impedance Variation)	4.64	mill/cu.mm	4.7 - 6.0
	orpuscular Volume(MCV) ood/Derived from Impedance)	93.7	fL	78 - 100
	orpuscular Haemoglobin(MCH) ood/Derived from Impedance)	32.1	pg	27 - 32
concentr	orpuscular Haemoglobin ation(MCHC) ood/Derived from Impedance)	34.3	g/dL	32 - 36
RDW-C (EDTA Bl	V ood/Derived from Impedance)	13.6	%	11.5 - 16.0
RDW-SI (EDTA Bl	D ood/Derived from Impedance)	44.60	fL	39 - 46
	ukocyte Count (TC) ood/Impedance Variation)	6800	cells/cu.mm	4000 - 11000
Neutropl (EDTA Blo Cytometry)	ood∕Impedance Variation & Flow	58.3	%	40 - 75
Lympho (EDTA Bl <i>Cytometry</i>)	ood/Impedance Variation & Flow	29.7	%	20 - 45
Eosinopl (EDTA Bl <i>Cytometry</i>)	ood/Impedance Variation & Flow	3.2	%	01 - 06
Monocyt (EDTA Ble Cytometry)	ood/Impedance Variation & Flow	7.7	%	01 - 10



APPROVED BY

The results pertain to sample tested.

Page 1 of 7

Name	: Mr. SRINIVASAN R		
PID No.	: MED110975721	Register On : 23/02/2022 11:12 AM	\mathbf{C}
SID No.	: 1802207928	Collection On : 23/02/2022 11:38 AM	
Age / Sex	: 32 Year(s) / Male	Report On : 23/02/2022 10:07 PM	MEDALL
Туре	: OP	Printed On : 24/02/2022 9:57 AM	
Ref. Dr	: MediWheel		

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Basophils (EDTA Blood/Impedance Variation & Flow Cytometry)	1.1	%	00 - 02
INTERPRETATION: Tests done on Automated	Five Part cell count	er. All abnormal results a	are reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	3.96	10^3 / µl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	2.02	10^3 / µl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.22	10^3 / µl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.52	10^3 / µl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.07	10^3 / µl	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	307	10^3 / µl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	7.3	fL	7.9 - 13.7
PCT (EDTA Blood/Automated Blood cell Counter)	0.22	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Blood/Automated - Westergren method)	11	mm/hr	< 15
BUN / Creatinine Ratio	8.77		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	140.3	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126

INTERPRETATION: Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose, Fasting (Urine)	Positive(+)		Negative
(Urine - F/GOD - POD)			
Glucose Postprandial (PPBS)	201.3	mg/dL	70 - 140
(Plasma - PP/GOD-PAP)			



APPROVED BY

The results pertain to sample tested.

Page 2 of 7

Name :	Mr. SRINIVASAN R			
PID No. :	MED110975721	Register On : 23	3/02/2022 11:12 AM	m
SID No. :	1802207928	Collection On : 2	3/02/2022 11:38 AM	
Age / Sex :	32 Year(s) / Male	Report On : 2	3/02/2022 10:07 PM	MEDALL
Туре :	OP	Printed On : 2	4/02/2022 9:57 AM	
Ref. Dr	MediWheel			
<u>Investigati</u>	ion	<u>Observed</u> <u>Value</u>	<u>Unit</u>	Biological Reference Interval
Fasting bloo	as type, quantity and time of food d glucose level may be higher that	Postprandial glucose,	because of physiological s	nd drugs can influence blood glucose level. urge in Postprandial Insulin secretion, Insulin ation during treatment for Diabetes.
Urine Gluc (Urine - PP)	cose(PP-2 hours)	Positive(+)		Negative
	a Nitrogen (BUN) use UV/derived)	9.3	mg/dL	7.0 - 21
Creatinine (Serum/Modi		1.06	mg/dL	0.9 - 1.3
ingestion of	cooked meat, consuming Protein/	Creatine supplements, I	Diabetic Ketoacidosis, pro	evere dehydration, Pre-eclampsia, increased longed fasting, renal dysfunction and drugs e, chemotherapeutic agent such as flucytosine
Uric Acid		5.7	mg/dL	3.5 - 7.2
(Serum/Enzyr <u>Liver Fund</u>				
Bilirubin(T (Serum/DCA	· · · · · · · · · · · · · · · · · · ·	0.90	mg/dL	0.1 - 1.2
Bilirubin(I (Serum/Diazo	Direct) otized Sulfanilic Acid)	0.28	mg/dL	0.0 - 0.3
Bilirubin(I (Serum/Deriv		0.62	mg/dL	0.1 - 1.0
SGOT/AS' Aminotran (Serum/ <i>Modi</i>		50.4	U/L	5 - 40
SGPT/ALT (Serum/Modi	T (Alanine Aminotransferase)	68.9	U/L	5 - 41
-	ma Glutamyl Transpeptidase)) 64.8	U/L	< 55
Alkaline P (Serum/ <i>Modi</i>	hosphatase (SAP) ified IFCC)	106.1	U/L	53 - 128
Total Prote (Serum/Biure		7.63	gm/dl	6.0 - 8.0
Albumin (Serum/ <i>Brom</i>	nocresol green)	4.26	gm/dl	3.5 - 5.2
				k. D. Martin



APPROVED BY

The results pertain to sample tested.

Page 3 of 7

Name	: Mr. SRINIVASAN R		
PID No.	: MED110975721	Register On : 23/02/2022 11:12 AM	\mathbf{C}
SID No.	: 1802207928	Collection On : 23/02/2022 11:38 AM	
Age / Sex	: 32 Year(s) / Male	Report On : 23/02/2022 10:07 PM	MEDALL
Туре	: OP	Printed On : 24/02/2022 9:57 AM	
Ref. Dr	: MediWheel		

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Globulin (Serum/Derived)	3.37	gm/dL	2.3 - 3.6
A : G RATIO (Serum/Derived) <u>Lipid Profile</u>	1.26		1.1 - 2.2
Cholesterol Total (Serum/CHOD-PAP with ATCS)	225.0	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	193.0	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the "usual" circulating level of triglycerides during most part of the day.

HDL Cholesterol (Serum/Immunoinhibition)	46.9	mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 40 - 59 High Risk: < 40
LDL Cholesterol (Serum/ <i>Calculated</i>)	139.5	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL Cholesterol (Serum/Calculated)	38.6	mg/dL	< 30
Non HDL Cholesterol (Serum/ <i>Calculated</i>)	178.1	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220

(Path) 16296 0: 1

APPROVED BY

The results pertain to sample tested.

Page 4 of 7

Name	:	Mr. SRINIVASAN R				
PID No.	:	MED110975721	Register On	:	23/02/2022 11:12 AM	m
SID No.	:	1802207928	Collection On	:	23/02/2022 11:38 AM	
Age / Sex	:	32 Year(s) / Male	Report On	:	23/02/2022 10:07 PM	MEDALL
Туре	:	OP	Printed On	:	24/02/2022 9:57 AM	
Ref. Dr	:	MediWheel				
<u>Investig</u>	<u>ati</u>	on	<u>Observe</u> <u>Value</u>	<u>d</u>	<u>Unit</u>	Biological Reference Interval
2.It is the	su	TATION: 1.Non-HDL Choleste n of all potentially atherogenic p arget for cholesterol lowering the	proteins including L			c marker than LDL Cholesterol. rons and it is the "new bad cholesterol" and is
Total Ch Ratio (Serum/Ca		esterol/HDL Cholesterol	4.8			Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0
Triglyce (TG/HD (Serum/Ca	L)		4.1			Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
	DL	Cholesterol Ratio	3			Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0
<u>Glycosy</u>	lat	ed Haemoglobin (HbA1c)				
HbA1C (Whole Bl	loo	1/HPLC)	7.2		%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: >= 6.5
INTERP	RE	TATION: If Diabetes - Good co	ontrol : 6.1 - 7.0 % ,	Fa	ir control : 7.1 - 8.0 %, Poo	r control >= 8.1 %
	ed	Average Glucose	159.94		mg/dL	
INTERP	RF	TATION: Comments				

INTERPRETATION: Comments

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbA1C values. Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbA1c.

THYROID PROFILE / TFT

T3 (Triiodothyronine) - Total1.30ng/ml0.7 - 2.04(Serum/Chemiluminescent Immunometric Assay

(CLIA))

INTERPRETATION:

Comment :

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.



APPROVED BY

The results pertain to sample tested.

Page 5 of 7

Name	: Mr. SRINIVASAN R		
PID No.	: MED110975721	Register On : 23/02/2022 11:12 AM	M
SID No.	: 1802207928	Collection On : 23/02/2022 11:38 AM	
Age / Sex	: 32 Year(s) / Male	Report On : 23/02/2022 10:07 PM	MEDALL
Туре	: OP	Printed On : 24/02/2022 9:57 AM	
Ref. Dr	: MediWheel		
<u>Investiga</u>	ation	<u>Observed Unit</u> <u>Value</u>	<u>Biological</u> Reference Interval

µg/dl

(Serum[']/*Chemiluminescent Immunometric Assay* (*CLIA*)) **INTERPRETATION: Comment :** Total T4 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T4 is recommended as it is Metabolically active. **TSH (Thyroid Stimulating Hormone)** 3.49 μIU/mL 0.35 - 5.50 (Serum/*Chemiluminescent Immunometric Assay* (*CLIA*)) **INTERPRETATION:**

8.86

Reference range for cord blood - upto 20 1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester : 0.3-3.0 (Indian Thyroid Society Guidelines) **Comment :**

1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI. 2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM.The variation can be of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.

3.Values&lt0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.

Urine Analysis - Routine

T4 (Tyroxine) - Total

COLOUR (Urine)	Pale yellow		Yellow to Amber
APPEARANCE (Urine)	Clear		Clear
Protein (Urine/Protein error of indicator)	Negative		Negative
Glucose (Urine/GOD - POD)	Positive(+)		Negative
Pus Cells (Urine/Automated – Flow cytometry)	1 - 2	/hpf	NIL
Epithelial Cells (Urine/Automated – Flow cytometry)	Occasional	/hpf	NIL
RBCs (Urine/Automated – Flow cytometry)	NIL	/hpf	NIL
Casts (Urine/Automated – Flow cytometry)	NIL	/hpf	NIL



4.2 - 12.0

APPROVED BY

The results pertain to sample tested.

Page 6 of 7

MediWheel			
OP	Printed On	: 24/02/2022 9:57 AM	
32 Year(s) / Male	Report On	: 23/02/2022 10:07 PM	MEDALL
1802207928	Collection On	: 23/02/2022 11:38 AM	
MED110975721	Register On	: 23/02/2022 11:12 AM	M
Mr. SRINIVASAN R			
	MED110975721 1802207928 32 Year(s) / Male OP	MED110975721Register On1802207928Collection On32 Year(s) / MaleReport OnOPPrinted On	MED110975721 Register On : 23/02/2022 11:12 AM 1802207928 Collection On : 23/02/2022 11:38 AM 32 Year(s) / Male Report On : 23/02/2022 10:07 PM OP Printed On : 24/02/2022 9:57 AM

NIL

NIL

NIL

Others

Crystals

(Urine/Automated - Flow cytometry)

(Urine)

INTERPRETATION: Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.

/hpf



APPROVED BY

-- End of Report --

The results pertain to sample tested.

Page 7 of 7